父母产前抗抑郁药使用与子代神经发育障碍风险的系统综述与荟萃分析
父亲抗抑郁药使用也与ADHD和ASD风险增加相关,提示家族或遗传混杂可能。
要点
- 产前抗抑郁药暴露与子代ADHD和ASD风险轻度增加相关,但证据确定性低至极低。
- 校正母体精神疾病、家族遗传等混杂后,关联减弱或不再显著。
- 父亲抗抑郁药使用也与子代ADHD和ASD风险增加相关,提示负对照设计的重要性。
核心结论
- 产前抗抑郁药暴露与子代ADHD和ASD风险存在小幅关联,但校正混杂因素后关联减弱或不再显著。
- 父亲抗抑郁药使用(负对照)也与ADHD和ASD风险增加相关,提示家族或遗传混杂可能解释部分关联。
- 对于中重度抑郁孕妇,应继续抗抑郁药治疗,同时优化父母双方心理健康。
研究设计与样本
- 系统综述与荟萃分析,检索Embase、MEDLINE、PsycINFO和Web of Science从建库至2025年5月14日。
- 使用随机效应荟萃分析合并相对风险(RR),评估发表偏倚、亚组分析和Newcastle-Ottawa质量评估。
主要发现
- 高剂量与低剂量暴露之间ASD风险无显著差异,父亲围受孕抗抑郁药使用与ASD无显著关联。
- SSRI和非SSRI抗抑郁药均与ADHD和ASD风险增加相关;校正混杂后仅阿米替林和去甲替林与ADHD或ASD风险增加相关。
临床怎么用
- 对于中重度抑郁孕妇,应继续抗抑郁药治疗,不应因神经发育风险而轻易停药。
- 临床决策需权衡产前抗抑郁药暴露的微小风险与未经治疗抑郁对母婴的危害。
- 应关注父母双方心理健康,优化围产期精神健康管理以促进子代长期神经发育。
局限性
- 证据确定性低至极低。
- 观察性研究存在混杂因素(如母体精神疾病、家族遗传、误分类),校正后关联减弱或不再显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The potential risk of neurodevelopmental disorders following prenatal antidepressant exposure is concerning. Meta-analyses conducted in the past decade have had small study numbers and insufficient assessment of confounding by treatment indication. We aimed to synthesise risk of neurodevelopmental disorders, including ADHD and autism spectrum disorder (ASD), with antidepressant exposure before or during pregnancy in mothers and fathers, accounting for antidepressant classes, agents, dose, and confounding. METHODS: In this systematic review and meta-analysis, we searched Embase, MEDLINE, PsycINFO, and Web of Science from database inception to May 14, 2025, for studies that included mothers or fathers with antidepressant use before or during the pregnancy period and that reported data on neurodevelopmental disorders. Relative risks (RRs) were pooled using random-effect meta-analyses. We assessed publication bias, subgroup analyses, and quality assessment (Newcastle-Ottawa scale). No people with relevant lived experience were involved in the research and writing process. Only two studies reported ethnicity data. This study is registered with PROSPERO (CRD420251052595). FINDINGS: We identified 37 studies involving 648 626 antidepressant-exposed and 24 967 806 unexposed pregnancies (weighted average mean age 28·8 years, range 28·5-32·3). Prenatal antidepressant use was associated with a modestly increased risk of neurodevelopmental disorders in offspring (RR 1·13, 95% CI 1·08-1·18; k=2; I2=64·9%; p=0·051), including ADHD (1·35, 1·24-1·47; k=14; I2=90·2%; p<0·0001) and ASD (1·69, 1·24-2·30; k=25; I2=98·1%; p<0·0001), but not intellectual disabilities, motor disorders, or speech and language disorders. No significant difference in ASD risk was found between high-dose and low-dose exposure, and paternal antidepressant use around conception was not linked to ASD. Both SSRI and non-SSRI antidepressants exhibited increased risk for ADHD (SSRI 1·35, 1·20-1·51; k=11; I2=87·3%; p<0·0001; non-SSRI 1·41, 1·33-1·50; k=3; I2=0%; p=0·35) and ASD (SSRI 1·52, 1·39-1·65; k=21; I2=55·6%; p<0·0001; non-SSRI 1·19, 1·03-1·45; k=4; I2=0%; p=0·38). Notably, similar associations were found for pre-conception exposure. Observed associations were attenuated or became non-significant in sensitivity analyses accounting for confounding factors, such as maternal mental disorders, familial or genetic influences, and misclassification. Paternal antidepressant use during pregnancy served as a negative control and was associated with increased ADHD risk (1·46, 1·38-1·56; k=2; I2=25·3%; p=0·24) and ASD risk (1·28, 1·16-1·40; k=6; I2=35·0%; p=0·20). When confounding by indication was minimised, only amitriptyline and nortriptyline were associated with increased risk of ADHD (amitriptyline 1·74, 1·00-3·03) or ASD (amitriptyline and nortriptyline 2·02, 1·32-3·10), whereas no significant associations were found for specific SSRIs or SNRIs. The certainty of evidence was low to very low. INTERPRETATION: This systematic review and meta-analysis indicated a small association between antidepressants and ADHD or ASD, which was attenuated or became non-significant after adjusting for confounding factors. Antidepressant treatment should be continued for pregnant women with moderate-to-severe depression. Optimising both maternal and paternal mental health is essential for the child's long-term neurodevelopment. FUNDING: None.
引用
- Chan JKN, Zhong AHF, Lam JYH, et al. Maternal and paternal antidepressant use before and during pregnancy and offspring risk of neurodevelopmental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2026. PMID: 42134364. doi:10.1016/S2215-0366(26)00089-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。